Exploration of glucocorticoid combined with anticoagulation in acute/subacute severe cerebral venous thrombosis

doi:10.3969/j.issn.1006-7795.2023.02.015

Abstract

Abstract: Objective To preliminarily investigate the application of glucocorticoid combined with anticoagulant therapy in acute/subacute severe cerebral venous thrombosis (CVT) through a case series. Methods Ten patients with acute/subacute severe CVT who were successfully treated with glucocorticoid combined with anticoagulation were enrolled in this study. Neurological deficits, increased intracranial pressure, serum and cerebrospinal fluid inflammatory markers and adverse events were retrospectively analyzed before and after treatment and at 3 months after discharge. Results Compared with baseline, serum neutrophil-to-lymphocyte ratio（NLR） (P＜0.05),hypersensitive C-reactive protein（hs-CRP）(P＜0.01), interleukin 6（IL-6） (P＜0.01) and cerebrospinal fluid IL-6 (P＜0.01) were significantly decreased in 10 patients at 2 weeks after glucocorticoid pulse therapy; Modified Rankin Scale（mRS） (P＜0.01), National Institutes of Health Stroke Score（NIHSS） (P＜0.01) and intracranial pressure (P＜0.01) were significantly decreased at discharge. At 3 months after discharge, mRS （P＜0.01） and NIHSS （P＜0.01） further decreased. Ten patients had no steroid-related serious adverse reactions such as venous thrombosis recurrence, spontaneous fracture, or osteonecrosis during hospitalization and follow-up. Conclusion Short-term use of glucocorticoid combined with anticoagulation may be safe and effective in patients with acute/subacute severe CVT.

Key words: severe cerebral venous thrombosis, acute/subacute phase, glucocorticoid, anticoagulation, prognosis

CLC Number:

R743

Hu Shuyuan, Zhang Kaiyuan, Gu Yaqin, Li Jingka, Zhou Chen, Ji Xunming, Duan Jiangang. Exploration of glucocorticoid combined with anticoagulation in acute/subacute severe cerebral venous thrombosis[J]. Journal of Capital Medical University, 2023, 44(2): 280-288.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.02.015

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I2/280

References

［1］Hu S Y, Lee H, Zhao H P, et al. Inflammation and severe cerebral venous thrombosis［J］. Front Neurol, 2022, 13: 873802.
［2］Stam J, Majoie C B L M, Van Delden O M, et al. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study［J］. Stroke, 2008, 39(5):1487－1490.
［3］Kowoll C M, Kaminski J, Wei V, et al. Severe cerebral venous and sinus thrombosis: clinical course, imaging correlates, and prognosis［J］. Neurocrit Care, 2016, 25(3):392－399.
［4］Spadaro A, Scott K R, Koyfman A, et al. Cerebral venous thrombosis: diagnosis and management in the emergency department setting［J］. Am J Emerg Med, 2021, 47: 24－29.
［5］Coutinho J M, Zuurbier S M, Bousser M G, et al. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial［J］. JAMA Neurol, 2020, 77(8):966－973.
［6］Zhang X F, Ding R, Li H Y, et al. An association between inflammation and cerebral venous thrombosis: a retrospective study［J］. J Stroke Cerebrovasc Dis, 2021, 30(11):106084.
［7］Wang L Y, Duan J G, Bian T T, et al. Inflammation is correlated with severity and outcome of cerebral venous thrombosis［J］. J Neuroinflammation, 2018, 15(1):329.
［8］Duan J G, Leng X Y, Han Z P, et al. Identifying biomarkers associated with venous infarction in acute/subacute cerebral venous thrombosis［J］. Aging Dis, 2021, 12(1):93－101.
［9］Aguiar De Sousa D, Pereira-Santos M C, Serra-Caetano A, et al. Blood biomarkers associated with inflammation predict poor prognosis in cerebral venous thrombosis: a multicenter prospective observational study［J］. Eur J Neurol, 2021, 28(1):202－208.
［10］宁军, 段建钢, 吉训明. 伴静脉性脑出血的重症颅内静脉窦血栓形成一例［J］. 中国现代神经疾病杂志, 2018, 18(11):813－817.
［11］赵婷玉, 段建钢, 肖立坡, 等. 糖皮质激素治疗重症颅内静脉窦血栓形成的可行性探索［J］. 华西医学, 2020, 35(6):642－645.
［12］Fan Y H, Yu J, Chen H B, et al. Chinese stroke association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of cerebral venous sinus thrombosis［J］. Stroke Vasc Neurol, 2020, 5(2):152－158.
［13］Saposnik G, Barinagarrementeria F, Brown R D Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association［J］. Stroke, 2011, 42(4):1158－1192.
［14］Stanbury R M, Graham E M. Systemic corticosteroid therapy--side effects and their management［J］. Br J Ophthalmol, 1998, 82(6):704－708.
［15］Sparaco M, Feleppa M, Bigal M E. Cerebral venous thrombosis and headache--a case-series［J］. Headache, 2015, 55(6):806－814.
［16］Sinclair A J, Burdon M A, Nightingale P G, et al. Rating papilloedema: an evaluation of the Frisén classification in idiopathic intracranial hypertension［J］. J Neurol, 2012, 259(7):1406－1412.
［17］Palazzo P, Agius P, Ingrand P, et al. Venous thrombotic recurrence after cerebral venous thrombosis: a long-term follow-up study［J］. Stroke, 2017, 48(2):321－326.
［18］Ferro J M, Canho P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)［J］. Stroke, 2004, 35(3):664－670.
［19］Saghazadeh A, Hafizi S, Rezaei N. Inflammation in venous thromboembolism: cause or consequence?［J］. Int Immunopharmacol, 2015, 28(1):655－665.
［20］Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation［J］. Nat Med, 2011, 17(7):796－808.
［21］Xiao L P, Ji X M, Zhao H P, et al. A novel severe cerebral venous thrombosis rat model based on semi-ligation combined with ferric chloride and thrombin［J］. CNS Neurosci Ther, 2022, 28(12):2129－2140.
［22］Rashad S, Niizuma K, Sato-Maeda M, et al. Early BBB breakdown and subacute inflammasome activation and pyroptosis as a result of cerebral venous thrombosis［J］. Brain Res, 2018, 1699: 54－68.
［23］Nagai M, Terao S, Yilmaz G, et al. Roles of inflammation and the activated protein C pathway in the brain edema associated with cerebral venous sinus thrombosis［J］. Stroke, 2010, 41(1):147－152.
［24］Ding R, Ou W Y, Chen C W, et al. Endoplasmic reticulum stress and oxidative stress contribute to neuronal pyroptosis caused by cerebral venous sinus thrombosis in rats: involvement of TXNIP/peroxynitrite-NLRP3 inflammasome activation［J］. Neurochem Int, 2020, 141: 104856.
［25］Ding R, Li H Y, Liu Y Q, et al. Activating cGAS-STING axis contributes to neuroinflammation in CVST mouse model and induces inflammasome activation and microglia pyroptosis［J］. J Neuroinflammation, 2022, 19(1):137.
［26］Ferro J M, Bousser M G, Canho P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology［J］. Eur J Neurol, 2017, 24(10):1203－1213.
［27］Zhang B Z, Lang Y, Zhang W G L, et al. Characteristics and management of autoimmune disease-associated cerebral venous sinus thrombosis［J］. Front Immunol, 2021, 12: 671101.
［28］Aguiar De Sousa D, Mestre T, Ferro J M. Cerebral venous thrombosis in Behets disease: a systematic review［J］. J Neurol, 2011, 258(5):719－727.
［29］Brotman D J, Girod J P, Posch A, et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers［J］. Thromb Res, 2006, 118(2):247－252.
［30］Isidori A M, Minnetti M, Sbardella E, et al. Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect［J］. Eur J Endocrinol, 2015, 173(3):R101-R113.

[1]	Hu Zhengfang, Wang Juan, Jian Minyu, Han Ruquan. ffect of intraoperative oxygen concentration on postoperative neurological function and complications in patients undergoing cerebrovascular recanalization [J]. Journal of Capital Medical University, 2023, 44(5): 865-871.
[2]	Liang Fa, Wu Youxuan, Wang Xinyan, Jian Minyu, Liu Haiyang, Han Ruquan. Effects of emergency conversion to general anesthesia on neurological outcomes of patients with acute ischemic stroke undergoing mechanical thrombectomy [J]. Journal of Capital Medical University, 2023, 44(2): 237-243.
[3]	Qin Linhui, Li Ning, Yang Yu, Yang Yong, Ren Changhong. Limb remote ischemic perconditioning combined with remote ischemic postconditioning promotes neurogenesis in rat models of ischemic stroke [J]. Journal of Capital Medical University, 2023, 44(1): 54-61.
[4]	Li Xue, Fan Junfen, Wang Rongliang, Ma Qingfeng, Luo Yumin, Zhao Haiping. Epigenetic regulation of HDAC2 on TBC protein family members of neutrophils in patients with ischemic stroke [J]. Journal of Capital Medical University, 2023, 44(1): 62-71.
[5]	Jiang Fucheng, Huang Jyumei, Feng Yuexian, Zhong Hongliang, Jia Jianwen, Yang Hongchao, Liu He, Liu Yang. The evaluation of the efficacy and prognosis of conscious sedation in endovascular treatment in acute ischemic stroke [J]. Journal of Capital Medical University, 2023, 44(1): 72-77.
[6]	Li Sen, Guo Xuewen, Zhao Xin, Huang Anqi, Lin Jingge, Li Xingmao, Li Xiu, Du Yifeng, Zhao Yongmei, Bai Jie, Xia Zhangyong. Correlation between glycemic variability and neurological deterioration in patients with acute ischemic stroke and diabetes mellitus [J]. Journal of Capital Medical University, 2023, 44(1): 78-84.
[7]	Zhao Jizong. Current status and clinical research of brain-heart comorbid vascular diseases in China [J]. Journal of Capital Medical University, 2022, 43(5): 671-673.
[8]	Zhou Yifan, Jiang Huimin, Wei Huimin, Gu Yuhang, Hu Wenbo, Liu Lu, Zhou Chen, Ji Xunming. Strengthening research on the cerebral venous system improves the diagnosis and treatment of neurological diseases——anatomy, physiology, and clinical overview [J]. Journal of Capital Medical University, 2022, 43(4): 505-520.
[9]	Gu Qiang, Yu Xiaojun, Zhang Jin. Analysis of clinical characteristics and prognosis of the very old and young old patients with mild ischemic stroke [J]. Journal of Capital Medical University, 2022, 43(3): 474-479.
[10]	Zhao Wenbo, Ren Changhong, Li Sijie, Ma Hongrui, Ji Xunming. Research and application of a new technical system of hypoxic and ischemic conditioning for prevention and treatment of ischemic stroke——The Second Prize of 2020 National Science and Technology Progress [J]. Journal of Capital Medical University, 2022, 43(1): 1-5.
[11]	Li Zixiao, Zhao Xingquan, Wang Yongjun. Establishment and application of key technologies and systems for improving health care quality of cerebrovascular diseases——The Second Prize of 2020 National Science and Technology Progress [J]. Journal of Capital Medical University, 2022, 43(1): 6-12.
[12]	Meng Xia, Li Meng, Wang Jingjing, Zhang Jing, Chen Baian, Lu Jing. Similarities and differences of cerebral β-amyloid protein characteristics between 5xFAD transgenic mice and alzheimer's disease patients [J]. Journal of Capital Medical University, 2022, 43(1): 106-112.
[13]	Yang Nan, Ding Mao, Huang Yuyou, Fang Yalan, Shi Wenjuan, Zhao Yongmei. Effects of nitric oxide on nerve growth factor and brain derived neurotrophic factor expressions in rats with focal cerebral ischemia/reperfusion injury [J]. Journal of Capital Medical University, 2020, 41(6): 908-913.
[14]	Zhang Yingbin, Mo Linhong, Nie Yiqiu, Liu Aixian. Application of functional near-infrared spectroscopy in the treatment of mild cognitive impairment after stroke with repeated transcranial magnetic stimulation [J]. Journal of Capital Medical University, 2020, 41(6): 965-969.
[15]	Li Ming, Li Sijie, Wu Chuanjie, Zhao Wenbo, Gu Chaoxiong, Ji Xunming. Focusing on clinical problems and promoting the transformation of scientific and technological achievements——Professor Ji Xunming [J]. Journal of Capital Medical University, 2020, 41(5): 748-751.